BACKGROUND OF THE INVENTION
The chronic fatigue syndrome (CFS) has been recognized as an illness characterized by easy fatigability, prolonged lassitude and disturbances of sleep, sometimes but not always appearing to follow symptoms of an acute viral illness [Holmes et al, Ann Intern Med 108(3),
The present invention relates to compositions of polyamides and Peba, in particular substantially devoid of transparency, used for the injection-moulding of parts which exhibit an advantageous compromise between rigidity, impact, fatigue resistance and injectability, said compositions optionally
FIELD OF THE INVENTION
The present invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV (hereinafter "DPP-IV"), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Phase filing under 35 U.S.C. .sctn.371 of PCT/JP2010/054065 filed on Mar. 4, 2010; and this application claims priority to Application No. 2009-074210 filed in Japan on Mar. 25, 2009 under 35 U.S.C. .sctn.119; the entire contents
اكتب أحد الأعراض أو المرض واقرأ عن الأعشاب التي قد تساعد ، واكتب عشبًا واطلع على الأمراض والأعراض التي تستخدم ضدها. * تستند جميع المعلومات إلى البحوث العلمية المنشورة